Other Clinical Trial - Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Status Recruiting

Clinical Trial Summary

This study is to evaluate the clinical efficacy of Lifei Xiaoji Wan for advanced non-small cell lung cancer (NSCLC), establish the treatment scheme, and obtain high-quality clinical evidence.

Clinical Trial Description

Non-small cell lung cancer (NSCLC) is a disease with high morbidity and mortality, poor prognosis, and a lack of safe and effective treatment. Lifei Xiaoji Wan has significant advantages in the treatment of advanced NSCLC, but the a lack of high-level clinical evaluation evidence and accurate mechanism of action research. According to the previous animal experiments of the team, it was proved that Lifei Xiaoji Wan can significantly inhibit the tumor growth ability of lung cancer mice, and inhibit the proliferation, clonal formation, and migration ability of lung cancer cells. This topic intends to adopt the method of multicenter randomized controlled study to observe the Lifei Xiaoji Wan for advanced NSCLC patients' overall survival (OS), progression-free survival (PFS), Functional Assessment of Cancer Therapy-Lung (FACT-L), TCM symptoms and syndrome and safety, help to clarify the role of Lifei Xiaoji Wan in TCM prevention and treatment of lung cancer, can provide high-level evidence for TCM prevention and treatment of lung cancer research and clinical. ;

Study Design

Related Conditions & MeSH terms

Advanced Non Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung

Clinical Trial Details

NCT number	NCT06406166
Study type	Interventional
Source	Henan University of Traditional Chinese Medicine
Contact	Yuanyuan Wang, MD
Phone	0371-66248624
Email	40685685@qq.com
Status	Recruiting
Phase	N/A
Start date	June 1, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03326752` - Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC	Phase 1
Completed	`NCT02157883` - Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)	Phase 1
Completed	`NCT00072631` - Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT02163733` - Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer	Phase 1
Not yet recruiting	`NCT06107374` - Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG	Phase 2
Completed	`NCT01802632` - AZD9291 First Time In Patients Ascending Dose Study	Phase 1/Phase 2
Terminated	`NCT04785365` - Long-Term Follow-Up Study of Patients Receiving ATL001	Phase 2
Recruiting	`NCT04032847` - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC	Phase 1/Phase 2
Completed	`NCT01631136` - Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04239443` - Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer	Phase 2
Completed	`NCT03452150` - D-0316 First Time in Patients Ascending Dose Study	Phase 1
Completed	`NCT04144608` - Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT04755738` - Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer	Phase 2
Completed	`NCT03652857` - Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer	Phase 2
Completed	`NCT03351361` - Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients	Phase 3
Completed	`NCT02407327` - Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Active, not recruiting	`NCT02143466` - AZD9291 in Combination With Ascending Doses of Novel Therapeutics	Phase 1
Recruiting	`NCT05004974` - Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer	Phase 2
Recruiting	`NCT05777603` - Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT04886401` - Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC